基于脂质纳米颗粒的多尺度系统性免疫编程用于癌症治疗
Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy.
目前,肿瘤免疫治疗的临床适用范围受到脱靶毒性、实体瘤中的物理屏障以及个性化细胞疗法复杂制造工艺的限制。
英文原题:Smart Biomaterials as Immunomodulators in Cancer Therapy.
免疫疗法融入肿瘤学,通过利用免疫系统选择性清除恶性细胞,彻底改变了癌症治疗。
免疫疗法融入肿瘤学领域,通过利用免疫系统选择性清除恶性细胞,彻底改变了癌症治疗格局。尽管取得了显著进展,传统免疫疗法仍受限于应答率有限、肿瘤异质性以及严重的全身毒性,包括细胞因子释放综合征和自身免疫。为应对这些挑战,智能生物材料已作为能够高精度调控免疫应答的下一代平台崭露头角。通过实现治疗药物的局部化和可控释放,这些系统增强了药物在肿瘤部位的滞留,减少了全身暴露并最大限度地降低了脱靶效应。工程化生物材料,包括脂质体、聚合物纳米颗粒、水凝胶、微针阵列和可植入支架,为细胞因子、检查点抑制剂、工程化 T 细胞和癌症疫苗的递送提供了空间和时间上的控制。这些平台改善了药代动力学和生物分布,同时促进了与肿瘤微环境的交互对话,从而增强了治疗效力并减少了不良反应。近期创新,如用于 mRNA 疫苗的脂质纳米颗粒和活性氧响应性水凝胶,凸显了这些材料的转化潜力,目前已有多种制剂进入临床试验阶段。本综述综合了智能生物材料作为免疫调节剂在设计与应用方面的当前进展,强调其克服癌症免疫治疗中主要临床障碍的能力。重点关注领域包括改善免疫细胞募集、增强抗原呈递以及整合多模式治疗的策略。通过将材料科学与免疫肿瘤学相结合,智能生物材料代表了一种实现更安全、更持久和更个性化癌症治疗的变革性方法。该领域的持续创新有望重塑治疗格局并加速临床转化。
The integration of immunotherapy into oncology has transformed cancer treatment by harnessing the immune system to selectively eliminate malignant cells. Despite remarkable advances, conventional immunotherapies remain constrained by limited response rates, tumour heterogeneity and severe systemic toxicities, including cytokine release syndrome and autoimmunity. To address these challenges, smart biomaterials have emerged as next-generation platforms capable of modulating immune responses with high precision. By enabling localised and controlled release of therapeutic agents, these systems enhance drug retention at tumour sites, reduce systemic exposure and minimise off-target effects. Engineered biomaterials, including liposomes, polymeric nanoparticles, hydrogels, microneedle arrays and implantable scaffolds, provide spatial and temporal control over the delivery of cytokines, checkpoint inhibitors, engineered T cells and cancer vaccines. These platforms improve pharmacokinetics and biodistribution while also facilitating crosstalk with the tumour microenvironment, thereby enhancing therapeutic potency and reducing adverse effects. Recent innovations such as lipid nanoparticles for mRNA-based vaccines and reactive oxygen species-responsive hydrogels highlight the translational potential of these materials, with several formulations now advancing into clinical trials. This review synthesises current progress in the design and application of smart biomaterials as immunomodulators, emphasising their capacity to overcome major clinical barriers in cancer immunotherapy. Key areas of focus include strategies to improve immune cell recruitment, enhance antigen presentation and integrate multimodal therapies. By bridging materials science and immuno-oncology, smart biomaterials represent a transformative approach to achieving safer, more durable and personalised cancer treatments. Continued innovation in this field is poised to reshape the therapeutic landscape and accelerate clinical translation.
MEMBER ACCOUNT
登录成功会直接打开下一页。